mardi 1 août 2017

Onco Actu du 1er août 2017

1. Biologie

Cell insights suggest how body may spot early cancer signs [University of Edimburgh]

2.6 Etiologie - Environnement

Trump Wants the EPA Radon Program Cut. So Do Some Scientists [Wired]

3.1 Tabac

Stanford tobacco expert discusses the FDA’s new tobacco and nicotine regulation plan [Stanford Medicine]

The FDA wants to cut cigarettes’ nicotine levels. Will that help people quit? [STAT]

4. Dépistage, diagnostic et pronostic

What is overdiagnosis and why should we take it seriously in cancer screening? [Public Health Research & Practice]

5.12.1 Immunothérapies - partenariats

With Clovis team-up, Bristol-Myers' Opdivo eyes dynamic-duo attack on a trio of cancers [FiercePharma]

Bristol-Myers, Clovis leap into PhIII combo studies in a PD-1/PARP play as rivals circle [EndPoint]

Bristol-Myers Squibb and Clovis Oncology Announce a Broad Clinical Collaboration to Evaluate Combination of Opdivo (Nivolumab) and Rubraca® (Rucaparib) in Phase 2 and Pivotal Phase 3 Clinical Trials in Multiple Tumor Types [BMS]

5.12.2 Immunothérapies - CAR-T

Kite Files the Industry's First CAR-T Marketing Authorization Application in Europe for Axicabtagene Ciloleucel [Kite]

Kite shoots for first CAR-T OK in Europe, staying one step behind Novartis in US race [EndPoints]

5.2 Pharma

AstraZeneca rally continues as US regulator endorses cancer drug [The Telegraph]

Acalabrutinib granted Breakthrough Therapy Designation by US FDA for the treatment of patients with mantle cell lymphoma [AstraZeneca]

AstraZeneca drug gets breakthrough status in early lung cancer [Reuters]

After Mystic setback, MedImmune takes on new FDA, academic immuno-oncology execs [FierceBiotech]

AstraZeneca and MedImmune strengthen immuno-oncology leadership with appointment of two renowned experts [AstraZeneca]

5.2.3 Pharma - économie

Loxo beefs up its genetics-based cancer drug pipeline with an unusual $40M deal [EndPoint]

Redx sells cancer drug to Loxo to escape debt crisis [FierceBiotech]

5.3 Traitements - FDA, EMA, NICE...

FDA advances two more Herceptin biosims—this time from Amgen and Teva—as Roche braces for impact [FiercePharma]

U.S. FDA to review Teva and Celltrion's cancer biosimilar drug [Reuters]

5.4 Traitements - Economie

Non-Small Cell Lung Cancer (NSCLC) Drugs Market Forecast 2017-2027 [ReportLinker]

6. Lutte contre les cancers

FDA, ASCO to Hold Geriatric Oncology Workshop on November 6 [ASCO in Action]

New Recommendations for Controlling Nausea and Vomiting Related to Cancer Treatment [ASCO]

6.1 Observation

Decline in U.S. life expectancy deserves more local and national attention [STAT]

6.6 Publications

Peer-Review Fraud Scheme Uncovered in China [The Scientist]

The One-Percent Club For Top-Cited Papers [The Scholarly Kitchen]

6.9 Controverses

'There are things worse than death': can a cancer cure lead to brutal bioweapons? [The Guardian]